COR vs STLN: fair value comparison
Cencora, Inc. and The Oncology Institute, Inc. · Updated 2026-10-19
STLN has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, STLN currently ranks higher by quality score.
| COR | STLN | |
|---|---|---|
| Verdict | Fairly valued | No estimate yet |
| Last price | $323.85 | $6.43 |
| 12-month range | $252.74–$374.75 | $2.38–$7.05 |
| Rank by discount to fair value | #58 of 108 Healthcare | — |
| Rank by quality score | #282 of 301 Healthcare | #281 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | High | Low |
| Margin trend | Stable | — |
| Revenue growth | Modest | — |
| RSI zone | Overbought | Neutral |
| 50/200-day trend | — | Uptrend |
| DCF cross-check | Overvalued | — |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: COR fair value analysis · STLN fair value analysis